Markers of inflammation and immune activation in chronic fatigue and chronic fatigue syndrome

Journal of Rheumatology

Volumn 24, Issue 2, 1997, Pages 372-376

  Buchwald, Dedra ^a,b,e   Wener, Mark H ^c,d   Pearlman, Tsilke ^a   Kith, Phalla ^e  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Chronic Fatigue Clinic   (United States)

^c Depts of Med and Lab Medicine

^d Clinical Immunology Laboratory   (Netherlands)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

chronic fatigue syndrome; cytokines; immunology; interleukin

Indexed keywords

BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; NEOPTERIN;

ADULT; ARTICLE; CHRONIC FATIGUE SYNDROME; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNE RESPONSE; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; BETA 2-MICROGLOBULIN; BIOLOGICAL MARKERS; BIOPTERIN; C-REACTIVE PROTEIN; CHRONIC DISEASE; DIAGNOSIS, DIFFERENTIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FATIGUE; FATIGUE SYNDROME, CHRONIC; FEMALE; HUMANS; IMMUNITY; INTERLEUKIN-6; MALE; NEOPTERIN; RECEPTORS, INTERLEUKIN-2;

EID: 0031054858     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Holmes GP, Kaplan JE, Gantz NM, et al: Chronic fatigue syndrome: A working case definition. Ann Intern Med 1988;108:387-9.
2. Schluederberg A, Straus S, Peterson P, et al: Chronic fatigue syndrome research: Definition and medical outcome assessment. Ann Intern Med 1992;117:325-31.
3. Komaroff AK, Buchwald D: Symptoms and signs of chronic fatigue syndrome. Rev Infect Dis 1991;13:S8-11.
4. Komaroff AL: Chronic fatigue syndromes: Relationship to chronic viral infections. J Virol Methods 1988;21:3-10.
5. Chronic fatigue syndrome: A pamphlet for physicians. Bethesda: US Department of Health and Human Services, 1990; National Institutes of Health Publication No. 90-484.
6. Aoki T, Usuda Y, Miyakoshi H, Tamura K, Herberman RB: Low natural killer syndrome: Clinical and immunologic features. Nat Immun 1987;6:116-28.
7. Borysiewicz LK, Haworth SJ, Cohen J, Mundin J, Rickinson A, Sissons JGP: Epstein-Barr virus-specific immune defects in patients with persistent symptoms following infectious mononucleosis. Q J Med 1986;58:111-21.
8. Jones JF, Ray G, Minnich LL, Hicks MJ, Kibler R, Locas DO: Evidence for active Epstein-Barr virus infection in patients with persistent, unexplained illnesses: Elevated anti-early antigen antibodies. Ann Intern Med 1985;102:1-7.
9. Straus SE, Tosato G, Armstrong G, et al:Persisting illness and fatigue in adults with evidence of Epstein-Barr virus infection. Ann Intern Med 1985;102:7-16.
10. Ho-Yen DO, Carrington D, Armstrong AA: Myalgie encephalitis and alpha-interferon. Lancet 1988;1:125.
11. Lloyd A, Abi Hanna D, Wakefield D: Interferon and myalgic encephalomyelitis. Lancet 1988;1:471.
12. Straus SE, Dale JK, Peter JB, Dinarello CA: Circulating lymphokine levels in the chronic fatigue syndrome (letter). J Infect Dis 1989;160:1085-6.
13. Lloyd A, Hickie I, Brockman A, Dwyer J, Wakefield D: Cytokine levels in serum and cerebrospinal fluid in patients with chronic fatigue syndrome (letter). J Infect Dis 1991;164:1023-4.
14. Linde A, Andersson B, Svenson SB, et al: Serum levels of lymphokines and soluble cellular receptors in primary Epstein-Barr virus infection and in patients with chronic fatigue syndrome. J Infect Dis 1992;165:994-1000.
15. Chao CC, Janoff EN, Hu S, et al: Altered cytokine release in periperal blood mononuclear cell cultures from patients with the chronic fatigue syndrome. Cytokine 1991;3:292-8.
16. Chao CC, Gallagher M, Phair J, Peterson PK: Serum neopterin and interleukin-6 levels in chronic fatigue syndrome (letter). J Infect Dis 1990;162:1412-3.
17. Cheney PR, Dorman SE, Bell DS: Interleukin-2 and the chronic fatigue syndrome. Ann Intern Med 1989;110:321.
18. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, 3rd ed, revised: DSM-III-R. Washington: American Psychiatric Association, 1987.
19. Robins LN, Heizer JE: Diagnostic Interview Schedule (DIS): Version III-A. St. Louis: Department of Psychiatry, Washington University School of Medicine, 1985.
20. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A: The chronic fatigue syndrome: A comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Case Definition Study Group. Ann Intern Med 1994;121:953-9.
21. MacDonald EM, Mann AH, Thomas HC: Interferons as mediators of psychiatric morbidity: An investigation in a trial of recombinant alpha-interferon in hepatitis B carriers. Lancet 1987;2:1175-8.
22. Wallace DJ, Margolin J, Waller P: Fibromyalgia and interleukin-2 therapy for malignancy (letter). Ann Intern Med 1988;106:909.
23. Denicoff KD, Rubinow DR, Papa MZ, et al: The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med 1987;107:293-300.
24. Rubin LA, Nelson DL: The soluble interleukin-2 receptor: Biology, function, and clinical application. Ann Intern Med 1990;113:619-27.
25. Fahey JL, Taylor JM, Detels R, et al: The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type I. N Engl J Med 1990;322:166-72.
26. 2 microglobulin: Its significance and clinical usefulness. Ann Clin Lab Sci 1990;20:163-6.
27. Tilg H, Wilmer A, Vogel W, et al: Serum levels of cytokines in chronic liver diseases. Gastroenterology 1992;105:310-1.
28. Oppenheim J, Rossio J, Gearing A, eds: Clinical Applications of Cytokines: Role in Pathogenesis, Diagnosis, and Therapy. Oxford: Oxford University Press, 1993.
29. Bauer J, Herrmann F: Interleukin-6 in clinical medicine. Ann Hematol 1991;62:203-10.
30. Bauer J, Lengyel G, Thung SN, Jonas U, Gerok W, Asc G: Human fetal heptocytes respond to inflammatory mediators and excrete bile. Hepatology 1991;13:1131-41.
31. Heinrich PC, Castell JV, Andus T: Interleukin-6 and the acute phase response. Biochem J 1990;265:621-36.
32. Straus SE, Fritz S, Dale JK, Gould B, Strober W: Lymphocyte phenotype and function in the chronic fatigue syndrome. J Clin Immunol 1992;13:30-40.
33. Landay AL, Jessop C, Lennette ET, Levy JA: Chronic fatigue syndrome: Clinical condition associated with immune activation. Lancet 1991;338:707-12.
34. Klimas NG, Salvato FR, Morgan R, Fletcher MA: Immunologic abnormalities in chronic fatigue syndrome. J Clin Microbiol 1990;28:1403-10.